Corgentech Files Registration Statement For $86.3 Million Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 4 /PRNewswire/ -- Corgentech Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for an initial public offering of shares of its common stock.
______________________
From S-1:
Corgentech is a biopharmaceutical company focused on the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. Our TF decoys are short strands of DNA that specifically bind to and block the activity of their target transcription factors. Transcription factors are widely recognized as excellent therapeutic targets because they control gene expression and biological processes. Because abnormal gene expression is a fundamental cause of many diseases, controlling the regulators, the transcription factors, offers an attractive therapeutic approach. We are focused on TF decoys initially for the treatment of cardiovascular disease, inflammatory disease, such as arthritis, and cancer.
We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology. Our lead product candidate, E2F Decoy, is currently in two Phase 3 clinical trials for the prevention of vein graft failure. In September 2003, we completed patient enrollment for both of our Phase 3 clinical trials. We are also developing E2F Decoy for the prevention of arterio-venous, or AV, graft failure and intend to begin Phase 1/2 clinical trials for this indication in the first half of 2004. E2F Decoy has received Fast Track designation from the FDA for both the prevention of vein graft failure and AV graft failure. We have entered into a world-wide collaborative agreement with Bristol-Myers Squibb Company, or BMS, for the development and commercialization of E2F Decoy for all indications. We also have additional TF decoys in preclinical development for the treatment of inflammatory diseases and cancer.
Symbol to be: CGTK
Credit Suisse First Boston, Lehman Brothers, CIBC World Markets and U.S. Bancorp Piper Jaffray are to underwrite the offering. |
